🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Steve, Tom and Julie were left with aphasia after their strokes. When the Words Away Went, follows their journeys as they prepare for some of the most challenging milestones in their recovery so far. Watch the film online now at stroke.org.uk or stream on Channel 4.

We wish Sarah a great day at Massachusetts General Hospital as she speaks to their Department of Neurology on MultiStem Cell Therapy for the Treatment of Acute Neurological Indications! #MultiStem #CellTherapy #Neurology

Today we remember and honor all those affected by the events of 9/11.

Reminder: The interim analysis of the MASTERS-2 trial will determine whether the current proposed study size is still sufficiently powered to achieve statistical significance following the change in primary endpoint. We expect these results to be available in October. #MultiStem

We were excited to share the news about Newcastle University's kidney study grant last week, as preclinical research has shown MultiStem may be beneficial in organ transplants. This research is also highly relevant to our Phase 2 clinical trial in trauma which assesses acute kidney

More people are surviving stroke because of increased public awareness, better treatment and coordinated systems of care. But four in 10 Canadians do not know any of the FAST signs of stroke. Help us share this life-saving message. Learn more: bit.ly/41B63yO.

High blood pressure causes no symptoms and nearly half of all people living with the deadly condition don’t know they have it. A new report by World Health Organization (WHO) in partnership with Resolve to Save Lives sheds light on the cause of half of all strokes - and the race to stop it. bit.ly/44W2Z0L

Following major injuries or systemic infections, the immune system may react in a harmful manner. Factors expressed by MultiStem cells have the potential to deliver therapeutic benefit in several ways, such as reducing acute inflammation while also promoting tissue repair.

Reminder: Our Annual Meeting of the Stockholders is next Wednesday, 9/27 at 8:30 AM ET. The meeting will be open to both stockholders and guests. If you are a stockholder and wish to vote during the meeting, you will need to join with your control number. buff.ly/46lkHfh

The American Stroke Association has a number of great resources for stroke patients and caregivers, including a directory of local support groups. Find the support group nearest to you here: buff.ly/3LzV7LP

Tomorrow is our Annual Meeting of Stockholders. The meeting will begin at 8:30 a.m. ET. If you're a stockholder, please have your control number ready. Both stockholders and guests can join 15 minutes prior to the start of the meeting here: virtualshareholdermeeting.com/ATHX2023

Our Annual Meeting will begin at 8:30 a.m. ET this morning. Stockholders and guests can join beginning now here: virtualshareholdermeeting.com/ATHX2023

We hosted our 2023 Annual Meeting of Stockholders yesterday. In case you missed it, you can listen to a replay here - buff.ly/45WRp73

Van had a stroke early on a Monday morning. His wife, Angela, knew the signs and acted fast. Thanks to her, he got clot-busting medication within an hour. He was home by Saturday with no physical or cognitive impairments. Read his Story from the Heart: spr.ly/6011uH3GN

We are excited to announce that Jane Wasman, JD, has been appointed Athersys Board Chair. Read more here: buff.ly/3F2IxB0

Athersys Licenses its Animal Health Assets to Ardent Animal Health buff.ly/3F31PX2

We're excited for Alliance for Regenerative Medicine (ARM)’s #CGMesa23 next week! Looking forward to connecting with senior executives and key stakeholders in the cell and gene therapy industry. Learn more: meetingonthemesa.com

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios businesswire.com/news/home/2023…

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives buff.ly/3Q2856i

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights buff.ly/3SM2HY1